Clinical trial
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose…
NCT00199888 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00199888 |
|---|---|
| Title | Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. |
| Official title | Pilot Study of Iodine-124 Labeled Chimeric G250 (124I-cG250) in Presurgical Patients With Renal Masses |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney, Renal Neoplasms, Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | 124-Iodine-cG250 (124I-cG250) |
| Enrollment | 26 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | May 29, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: